Summary

• After reaching a cycle high of $141.23 per share in early March 2025, Abbott Laboratories closed at $92.48 as of April 23rd, the equivalent of a ~35% decline in just over a year.
• This is now one of the most severe drawdowns in the company's history, even exceeding in severity the price declines experienced during the 2008-09 global financial crisis.
• Along with the release of the Q1-26 earnings last week, management has guided for adjusted diluted EPS between $5.38 and $5.58 per share in fiscal 2026.
• Abbott is currently trading at 16.9x and 15.2x forward earnings for fiscal 2026 and 2027, respectively. Comparable net sales growth is expected between +6.5% and +7.5% in fiscal 2026.
• I have purchased my first ABT shares today at an average price of $90.81. It remains to be seen whether or not today's low of $90.72 will hold, but in any case, I plan to further increase my position if the share price continues to drift lower.

Caught In A Severe Drawdown

After initiating Novo Nordisk (NVO) with a 'Buy' rating earlier this month, I now turn my attention to another beaten-down healthcare giant, namely Abbott Laboratories (

2.74K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.